Ideal SARS-CoV-2 therapeutic antibodies would have high potency in viral neutralization against several emerging variants. Therapeutics against variants of SARS-CoV-2 are urgently needed. ![]() Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, several variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged and have consistently replaced the previous dominant variant. 4Beijing Kohnoor Science and Technology Co., Ltd., Beijing, China.3State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.2Key Laboratory of Special Pathogens and Biosafety, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.1Mabwell (Shanghai) Bioscience Co., Ltd., Shanghai, China. ![]() Wen Jiang 1 †, Zherui Zhang 2 †, Yuhe Zhu 3 †, Ben Chen 1, Chunying Gu 1, Zhiyan Liu 1, Xukai Zhang 1, Hualong Xiong 3, Yanan Zhang 2, Bin Zheng 1, Rongjuan Wang 1,4, Shasha Jiao 1,4, An Wang 1, Tianying Zhang 3, Jinchao Zhang 1, Shuang Wang 1,4*, Bo Zhang 2*, Gang Li 1* and Xun Gui 1*
0 Comments
Leave a Reply. |